Total Payments
$99,412
2024 Payments
$4,613
Companies
50
Transactions
1,321
Medicare Patients
2,964
Medicare Billing
$496,295
Payment Breakdown by Category
Other$43,325 (43.6%)
Food & Beverage$29,337 (29.5%)
Consulting$12,985 (13.1%)
Travel$7,991 (8.0%)
Research$5,541 (5.6%)
Education$233.22 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $41,525 | 29 | 41.8% |
| Food and Beverage | $29,337 | 1,250 | 29.5% |
| Consulting Fee | $12,985 | 10 | 13.1% |
| Travel and Lodging | $7,991 | 13 | 8.0% |
| Unspecified | $5,541 | 6 | 5.6% |
| Honoraria | $1,800 | 2 | 1.8% |
| Education | $233.22 | 11 | 0.2% |
Payments by Type
General
$93,872
1,315 transactions
Research
$5,541
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $39,616 | 44 | $0 (2024) |
| Janssen Biotech, Inc. | $9,607 | 110 | $0 (2024) |
| PFIZER INC. | $6,248 | 142 | $0 (2024) |
| Eli Lilly and Company | $5,541 | 6 | $0 (2021) |
| Ultragenyx Pharmaceutical Inc. | $5,437 | 5 | $0 (2021) |
| Janssen Research & Development, LLC | $5,303 | 8 | $0 (2017) |
| UCB, Inc. | $4,785 | 113 | $0 (2024) |
| Amgen Inc. | $4,166 | 172 | $0 (2024) |
| ABBVIE INC. | $2,871 | 109 | $0 (2024) |
| Lilly USA, LLC | $1,884 | 82 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,613 | 144 | Amgen Inc. ($827.84) |
| 2023 | $14,221 | 127 | Janssen Biotech, Inc. ($5,021) |
| 2022 | $19,364 | 108 | Janssen Scientific Affairs, LLC ($15,783) |
| 2021 | $29,014 | 221 | Janssen Scientific Affairs, LLC ($19,934) |
| 2020 | $7,174 | 146 | Janssen Biotech, Inc. ($2,901) |
| 2019 | $6,913 | 185 | Eli Lilly and Company ($1,901) |
| 2018 | $9,120 | 188 | Eli Lilly and Company ($3,639) |
| 2017 | $8,993 | 202 | Janssen Research & Development, LLC ($5,303) |
All Payment Transactions
1,321 individual payment records from CMS Open Payments — Page 1 of 53
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: Immunology | ||||||
| 12/19/2024 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $28.14 | General |
| Category: Endocrinology | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $44.03 | General |
| Category: Immunology | ||||||
| 12/04/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $28.08 | General |
| Category: Rheumatology | ||||||
| 12/03/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: IMMUNOLOGY | ||||||
| 11/25/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/22/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $90.94 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 11/22/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $26.35 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $19.11 | General |
| Category: Immunology | ||||||
| 11/20/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $29.25 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $18.55 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/16/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/16/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $123.59 | General |
| Category: Immunology | ||||||
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $17.18 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 11/12/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $24.38 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/11/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $235.00 | General |
| 11/08/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $27.36 | General |
| 11/05/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $24.22 | General |
| Category: Bone Health | ||||||
| 11/04/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $23.28 | General |
| Category: Immunology | ||||||
| 11/01/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $30.15 | General |
| Category: IMMUNOLOGY | ||||||
| 10/30/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $25.41 | General |
| Category: IMMUNOLOGY | ||||||
| 10/28/2024 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $22.78 | General |
| Category: Endocrinology | ||||||
| 10/24/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $25.65 | General |
| Category: IMMUNOLOGY | ||||||
| 10/23/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $43.78 | General |
| Category: Immunology | ||||||
| 10/17/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $27.25 | General |
| Category: Inflammation and Autoimmunity | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A 52 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IXEKIZUMAB LY2439821 IN BDMARD NAIVE PATIENTS WITH NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | Eli Lilly and Company | $2,481 | 1 |
| A MULTICENTER LONG-TERM EXTENSION STUDY OF 104 WEEKS INCLUDING A DOUBLE BLIND PLACEBO CONTROLLED 40 WEEK RANDOMIZED WITHDRAWAL RETREATMENT PERIOD TO EVALUATE THE MAINTENANCE OF TREATMENT EFFECT OF IXEKIZUMAB LY2439821 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS | Eli Lilly and Company | $1,902 | 2 |
| A PHASE 3 MULTICENTER STUDY TO EVALUATE THE LONG TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | Eli Lilly and Company | $1,092 | 1 |
| A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CANCER | Eli Lilly and Company | $65.00 | 1 |
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY OF LY3471851 (NKTR 358) IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | Eli Lilly and Company | $0.80 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 364 | 2,316 | $290,054 | $80,507 |
| 2022 | 12 | 694 | 3,285 | $205,253 | $103,481 |
| 2021 | 14 | 987 | 5,478 | $347,226 | $177,628 |
| 2020 | 15 | 919 | 4,383 | $319,970 | $134,678 |
Total Patients
2,964
Total Services
15,462
Medicare Billing
$496,295
Procedure Codes
51
All Medicare Procedures & Services
51 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 21 | 1,740 | $92,237 | $32,538 | 35.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 122 | 244 | $106,240 | $25,090 | 23.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 50 | 50 | $39,599 | $9,197 | 23.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 55 | 86 | $26,462 | $6,294 | 23.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 21 | 23 | $10,695 | $3,328 | 31.1% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 24 | 41 | $7,298 | $2,306 | 31.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 20 | 24 | $4,573 | $1,118 | 24.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 23 | 40 | $2,000 | $478.75 | 23.9% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 15 | 19 | $361.00 | $116.81 | 32.4% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 13 | 49 | $588.00 | $41.18 | 7.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 39 | 2,340 | $58,500 | $39,464 | 67.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 210 | 396 | $83,160 | $37,387 | 45.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 130 | 164 | $22,960 | $11,009 | 47.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 41 | 41 | $14,350 | $6,525 | 45.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 20 | 25 | $6,500 | $3,565 | 54.8% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 41 | 60 | $8,400 | $2,935 | 34.9% |
| 20605 | Aspiration and/or injection of fluid from medium joint | Office | 2022 | 17 | 21 | $2,940 | $779.95 | 26.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 48 | 57 | $3,990 | $660.64 | 16.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 13 | 13 | $827.89 | $550.58 | 66.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 110 | 136 | $2,720 | $406.11 | 14.9% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2022 | 12 | 17 | $680.00 | $147.32 | 21.7% |
| 81002 | Urinalysis, manual test | Office | 2022 | 13 | 15 | $225.00 | $52.05 | 23.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 264 | 708 | $148,680 | $71,938 | 48.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 34 | 3,180 | $79,500 | $52,300 | 65.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 79 | 79 | $27,650 | $14,757 | 53.4% |
About Dr. Richard Roseff, MD
Dr. Richard Roseff, MD is a Rheumatology healthcare provider based in Danbury, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1720007560.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Roseff, MD has received a total of $99,412 in payments from pharmaceutical and medical device companies, with $4,613 received in 2024. These payments were reported across 1,321 transactions from 50 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($41,525).
As a Medicare-enrolled provider, Roseff has provided services to 2,964 Medicare beneficiaries, totaling 15,462 services with total Medicare billing of $496,295. Data is available for 4 years (2020–2023), covering 51 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Other Specialties Rheumatology
- Location Danbury, CT
- Active Since 07/19/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RR0500X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1720007560
Products in Payments
- SIMPONI ARIA (Biological) $28,301
- TREMFYA (Drug) $19,314
- XELJANZ (Drug) $5,893
- TALTZ (Drug) $5,729
- Cimzia (Drug) $3,212
- Enbrel (Biological) $1,938
- Durolane (Device) $1,536
- RINVOQ (Biological) $1,533
- Zilretta (Drug) $1,325
- ACTHAR (Biological) $1,179
- BENLYSTA (Biological) $1,027
- STELARA (Biological) $961.34
- COSENTYX (Biological) $809.94
- EVENITY (Biological) $763.81
- SAPHNELO (Biological) $706.09
- Otezla (Drug) $620.79
- REMICADE (Biological) $578.91
- COSENTYX (Drug) $529.32
- ORENCIA (Biological) $500.81
- FORTEO (Drug) $494.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Danbury
Dr. Michael Spiegel, M.d, M.D
Rheumatology — Payments: $304,296
Rheumatology $304,296
Alla Rudinskaya, M.d, M.D
Rheumatology — Payments: $2,099
Rheumatology $2,099
David Trock, M.d, M.D
Rheumatology — Payments: $1,350
Rheumatology $1,350
Jesse Dabit, Md, MD
Rheumatology — Payments: $670.34
Rheumatology $670.34
Anne Liebling, Md, MD
Rheumatology — Payments: $125.00
Rheumatology $125.00
Dr. Kenneth Miller, Md, MD
Rheumatology
Rheumatology